Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 9, September, p. 1057–1063

doi: 10.17219/acem/125397

Publication type: original article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Enzyme activity and genetic polymorphisms in patients with type II diabetes mellitus

Abdullah Arpaci1,A,B,C,D,E,F, Serap Yalın2,C, Hasret Ecevit3,D,E,F, Ulku Comelekoglu4,A,E, Turkan Mete5,A,B

1 Department of Biochemistry, Medical Faculty, Hatay Mustafa Kemal University, Turkey

2 Department of Biochemistry, Pharmacy Faculty, Mersin University, Turkey

3 Department of Medical Biology, Medical Faculty, Hatay Mustafa Kemal University, Turkey

4 Department of Biophysics, Medical Faculty, Mersin University, Turkey

5 Department of Gastroenterology, Samsun Training and Research Hospital, Turkey

Abstract

Background. Diabetes mellitus (DM) has become more and more common and has a high morbidity and mortality rate worldwide. It is a multifactorial chronic disease affected by both genetic and environmental factors.
Objectives. To evaluate the association between antioxidant enzyme activities and their genetic variations and the level of malondialdehyde (MDA) in type II diabetes patients living in the Adıyaman province in the southeast part of Turkey.
Material and Methods. One hundred patients diagnosed with type II DM (T2DM) and 100 healthy controls were included in the study. Malondialdehyde levels and antioxidant enzyme activities were measured spectrophometrically. DNA isolation was performed and genotyping was carried out using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
Results. Our results revealed no significant differences in genotype distributions and allele frequencies of all polymorphisms between groups (p > 0.05). Significantly elevated MDA levels and a significant reduction in catalase (CAT) and paraoxonase (PON) enzyme activities were observed in patients compared to the control group in terms of study groups and genetic variations (p < 0.05). Moreover, CAT activity was reduced in TT genotype in terms of CAT -262 C/T polymorphism in patients (p < 0.05). Paraoxonase activity was observed to be lower in MM genotype in both groups (p < 0.05).
Conclusion. CAT -262 C/T polymorphism may be one of the factors that lead to severe clinical situation in DM. Our results suggest that TT genotype may be more prone to lipid peroxidation.

Key words

diabetes mellitus, oxidative stress, cat, malondialdehyde, paraoxonase

References (30)

  1. Gray SP, Jandeleit-Dahm K. The pathobiology of diabetic vascular complications: Cardiovascular and kidney disease. J Mol Med (Berl). 2014;92(5):441–452.
  2. Banerjee M, Vats P. Reactive metabolites and antioxidant gene polymorphisms in Type 2 diabetes mellitus. Redox Biol. 2014;2:170–177.
  3. Ahmed FN, Naqvi FN, Shafiq F. Lipid peroxidation and serum antioxidant enzymes in patients with type 2 diabetes mellitus. Ann N Y Acad Sci. 2006;1084:481–489.
  4. International Diabetes Federation. International Diabetes Federation Diabetes Atlas. 8th ed. International Diabetes Federation; 2017. https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/134-idf-diabetes-atlas-8th-edition.html. Chapter 1:18.
  5. Bednarek E, Sitkowski J, Bocian W, et al. Structure and pharmaceutical formulation development of a new long-acting recombinant human insulin analog studied by NMR and MS. J Pharm Biomed Anal. 2017;135:126–132.
  6. Tabatabaei-Malazy O, Khodaeian M, Bitarafan F, Larijani B, Amoli MM. Polymorphisms of antioxidant genes as a target for diabetes management. Int J Mol Cell Med. 2017;6(3):135–147.
  7. Van Dam PS, Van Asbeck BS, Erkelens DW, Marx JJ, Gispen WH, Bravenboer B. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev. 1995;11(3):181–192.
  8. Bullon P, Newman HN, Battino M. Obesity, diabetes mellitus, atherosclerosis and chronic periodontitis: A shared pathology via oxidative stress and mitochondrial dysfunction? Periodontol 2000. 2014;64(1):139–153.
  9. Yagi K. Simple procedure for specific assay of lipid hydroperoxides in serum or plasma. Methods Mol Biol. 1998;108:107–110.
  10. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121–126.
  11. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35(6):1126–1138.
  12. Poncz M, Solowiejczyk D, Harpel B, Mory Y, Schwartz E, Surrey S. Construction of human gene libraries from small amounts of peripheral blood: Analysis of beta-like globin genes. Hemoglobin. 1982;6(1):27–36.
  13. Lakshmy R, Ahmad D, Abraham RA, et al. Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infarction & association with oxidized low density lipoprotein. Indian J Med Res. 2010;131:522–529.
  14. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3(1):73–76.
  15. Goulas A, Fidani L, Kotsis A, et al. An association study of a functional catalase gene polymorphism, -262C-->T, and patients with Alzheimer’s disease. Neurosci Lett. 2002;330(2):210–213.
  16. Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes. 2015;6(6):850–867.
  17. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.
  18. Banerjee J, Mishra N, Damle G, et al. Beyond LDL-c: The importance of serum oxidized LDL in predicting risk for type 2 diabetes in the middle-aged Asian Indians. Diabetes Metab Syndr. 2019;13(1):206–213.
  19. Ghazizadeh Z, Khaloo P, Alemi H, et al. Definition of an oxidative stress status by combined assessment of malondialdehyde and oxidized-LDL: A study in patients with type 2 diabetes and control. Meta Gene. 2019;19:91–97.
  20. Kasznicki J, Sliwinska A, Kosmalski M, et al. Genetic polymorphisms (Pro197Leu of Gpx1, +35A/C of SOD1, -262C/T of CAT), the level of antioxidant proteins (GPx1, SOD1, CAT) and the risk of distal symmetric polyneuropathy in Polish patients with type 2 diabetes mellitus. Adv Med Sci. 2016;61(1):123–129.
  21. Tartan Z, Orhan G, Kasikcioglu H, et al. The role of paraoxonase (PON) enzyme in the extent and severity of the coronary artery disease in type-2 diabetic patients. Heart Vessels. 2007;22(3):158–164.
  22. Sozmen EY, Sozmen B, Delen Y, Onat T. Catalase/superoxide dismutase (SOD) and catalase/paraoxonase (PON) ratios may implicate poor glycemic control. Arch Med Res. 2001;32(4):283–287.
  23. Memisogullari R, Taysi S, Bakan E, Capoglu I. Antioxidant status and lipid peroxidation in type II diabetes mellitus. Cell Biochem Funct. 2003;21(3):291–296.
  24. Flekac M, Skrha J, Hilgertova J, Lacinova Z, Jarolimkova M. Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus. BMC Med Genet. 2008;9:30.
  25. Tarnai I, Csordas M, Sukei E, Shemirani AH, Káplár M, Góth L. Effect of C111T polymorphism in exon 9 of the catalase gene on blood catalase activity in different types of diabetes mellitus. Free Radic Res. 2007;41(7):806–811.
  26. Houldsworth A, Hodgkinson A, Demaine A, et al. Catalase polymorphism may influence the pathogenesis of diabetes mellitus. J Endocrinol Diabetes. 2016;3(6):1–7.
  27. dos Santos KG, Canani LH, Gross JL, et al. The catalase -262C/T promoter polymorphism and diabetic complications in Caucasians with type 2 diabetes. Dis Markers. 2006;22(5–6):355–359.
  28. Pask R, Cooper JD, Walker NM, et al. No evidence for a major effect of two common polymorphisms of the catalase gene in type 1 diabetes susceptibility. Diabetes Metab Res Rev. 2006;22(5):356–360.
  29. Gupta N, Binukumar BK, Singh S, et al. Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a North-West Indian population. Gene. 2011;487(1):88–95.
  30. Altuner D, Ates I, Suzen SH, Koc GV, Aral Y, Karakaya A. The relationship of PON1 QR 192 and LM 55 polymorphisms with serum paraoxonase activities of Turkish diabetic patients. Toxicol Ind Health. 2011;27(10):873–878.
© Wroclaw Medical University